{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:58:40Z","timestamp":1790614720468,"version":"4.1.0"},"reference-count":102,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BTT"],"DOI":"10.2147\/btt.s539066","type":"journal-article","created":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:15:12Z","timestamp":1768288512000},"page":"1-15","source":"Crossref","is-referenced-by-count":2,"title":["Teclistamab for Relapsed or Refractory Multiple Myeloma: A Review of Efficacy, Safety, Resistance Mechanisms and Future Directions"],"prefix":"10.2147","volume":"Volume 20","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-7960-7330","authenticated-orcid":true,"given":"B\u00e9n\u00e9dicte","family":"Piron","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrille","family":"Touzeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,1]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1038\/s41375-022-01531-2","volume":"36","author":"Mateos","year":"2022","journal-title":"Leukemia"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1470-2045(19)30788-0","volume":"21","author":"Lonial","year":"2020","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/NEJMoa2203478","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1200\/JCO.24.01008","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa2303379","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1080\/14712598.2019.1641196","volume":"19","author":"Tai","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"7333","DOI":"10.1038\/ncomms8333","volume":"6","author":"Laurent","year":"2015","journal-title":"Nat Commun"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"5145","DOI":"10.1073\/pnas.1220145110","volume":"110","author":"Labrijn","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.clim.2006.09.001","volume":"122","author":"Kim","year":"2007","journal-title":"Clin Immunol Orlando Fla"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"4593","DOI":"10.3390\/jcm10194593","volume":"10","author":"Hosny","year":"2021","journal-title":"J Clin Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"580","DOI":"10.3389\/fimmu.2016.00580","volume":"7","author":"Saxena","year":"2016","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"4538","DOI":"10.1182\/bloodadvances.2020002393","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e13717","DOI":"10.1111\/cts.13717","volume":"17","author":"Guo","year":"2024","journal-title":"Clin Transl Sci"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1200\/JCO.2024.42.16_suppl.7540","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s12325-023-02738-0","volume":"41","author":"Moreau","year":"2024","journal-title":"Adv Ther"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/s41375-024-02154-5","volume":"38","author":"Riedhammer","year":"2024","journal-title":"Leukemia"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3324\/haematol.2024.286118","volume":"110","author":"Perrot","year":"2024","journal-title":"Haematologica"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41408-025-01259-z","volume":"15","author":"Tan","year":"2025","journal-title":"Blood Cancer J"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"308.e1","DOI":"10.1016\/j.jtct.2023.12.016","volume":"30","author":"Dima","year":"2024","journal-title":"Transplant Cell Ther"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1038\/s41408-024-01003-z","volume":"14","author":"Mohan","year":"2024","journal-title":"Blood Cancer J"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"8011","DOI":"10.1200\/JCO.2023.41.16_suppl.8011","volume":"41","author":"Van De Donk","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"e136","DOI":"10.1002\/hem3.136","volume":"8","author":"Tomasson","year":"2024","journal-title":"HemaSphere"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"S2152265025042831","DOI":"10.1016\/j.clml.2025.11.004","author":"Lee","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"D\u2019Souza A, Costa LJ, San-Miguel JF, et al. Teclistamab, daratumumab, and pomalidomide in patients with relapsed\/refractory multiple myeloma: results from the MajesTEC-2 cohort A and TRIMM-2 studies. Blood 2024;144(Suppl 1):Abstract 495. Presented at: the 65th ASH Annual Meeting and Exposition. San Diego, CA; 2024.","DOI":"10.1182\/blood-2024-200181"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa2406536","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3408","DOI":"10.1182\/bloodadvances.2025016059","volume":"9","author":"Dima","year":"2025","journal-title":"Blood Adv"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1111\/bjh.19772","volume":"205","author":"Lebreton","year":"2024","journal-title":"Br J Haematol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1177\/10781552251341235","volume":"31","author":"Jiang","year":"2025","journal-title":"J Oncol Pharm Pract"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17474086.2025.2567296","author":"Dimopoulos","year":"2025","journal-title":"Expert Rev Hematol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1111\/ejh.14348","volume":"114","author":"Stalker","year":"2025","journal-title":"Eur J Haematol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1182\/blood.2023022937","volume":"143","author":"Forgeard","year":"2024","journal-title":"Blood"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287606","author":"Talbot","year":"2025","journal-title":"Haematologica"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287313","author":"Battaglini","year":"2025","journal-title":"Haematologica"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41408-025-01297-7","volume":"15","author":"Pasvolsky","year":"2025","journal-title":"Blood Cancer J"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"7506","DOI":"10.1200\/JCO.2024.42.16_suppl.7506","volume":"42","author":"Touzeau","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref39","unstructured":"Lachenal F, Gerome T, Chalopin T, et al. Effectiveness and safety of bispecific antibodies targeting BCMA and CD3 in patients with central nervous system multiple myeloma (CNS-MM): IFM 2023-06, a retrospective cohort study. Poster presented at: EHA 2024. Madrid, Spain; 2024."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.3324\/haematol.2020.248518","volume":"105","author":"Egan","year":"2020","journal-title":"Haematologica"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"e1220745","DOI":"10.1097\/01.HS9.0000970436.12207.45","volume":"7","author":"Wong","year":"2023","journal-title":"HemaSphere"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s40265-023-01954-w","volume":"83","author":"Dhillon","year":"2023","journal-title":"Drugs"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s40265-025-02207-8","volume":"85","author":"Lee","year":"2025","journal-title":"Drugs"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1182\/bloodadvances.2023012354","volume":"8","author":"Letouz\u00e9","year":"2024","journal-title":"Blood Adv"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1038\/s41591-023-02491-5","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1182\/blood.2024024582","volume":"144","author":"Ailawadhi","year":"2024","journal-title":"Blood"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Mateos MV, San-Miguel J, Dhakal B, et al. Overall survival with ciltacabtagene autoleucel versus standard of care in lenalidomide-refractory multiple myeloma: phase 3 CARTITUDE-4 study update. Presented at: the 21st International Myeloma Society Annual Meeting. Brazil: Rio de Janeiro; 2024.","DOI":"10.1016\/S2152-2650(24)02346-2"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1002\/cncr.34756","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3337","DOI":"10.1182\/blood-2024-206357","volume":"144","author":"Pasvolsky","year":"2024","journal-title":"Blood"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41408-023-00808-8","volume":"13","author":"Sim","year":"2023","journal-title":"Blood Cancer J"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.cmi.2024.02.023","volume":"30","author":"Jourdes","year":"2024","journal-title":"Clin Microbiol Infect off Publ Eur Soc Clin Microbiol Infect Dis"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3324\/haematol.2023.283590","volume":"109","author":"Hammons","year":"2023","journal-title":"Haematologica"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"2466","DOI":"10.1182\/bloodadvances.2021006178","volume":"6","author":"Mohan","year":"2022","journal-title":"Blood Adv"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1038\/s41408-024-01091-x","volume":"14","author":"Yee","year":"2024","journal-title":"Blood Cancer J"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41408-023-00879-7","volume":"13","author":"Raje","year":"2023","journal-title":"Blood Cancer J"},{"key":"ref58","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1182\/hematology.2023000433","volume":"2023","author":"Lee","year":"2023","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"ref59","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/j.ccell.2023.02.008","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"ref60","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"O\u2019Connor","year":"2004","journal-title":"J Exp Med"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"ref62","doi-asserted-by":"publisher","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"e205","DOI":"10.1016\/S1470-2045(24)00043-3","volume":"25","author":"Rodriguez-Otero","year":"2024","journal-title":"Lancet Oncol"},{"key":"ref64","doi-asserted-by":"publisher","first-page":"4720","DOI":"10.1182\/bloodadvances.2025016490","volume":"9","author":"Banerjee","year":"2025","journal-title":"Blood Adv"},{"key":"ref65","doi-asserted-by":"publisher","first-page":"e5193345","DOI":"10.1097\/01.HS9.0000972904.51933.45","volume":"7","author":"Frerichs","year":"2023","journal-title":"HemaSphere"},{"key":"ref66","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1182\/blood-2024-199374","volume":"144","author":"Cheruvalath","year":"2024","journal-title":"Blood"},{"key":"ref67","unstructured":"Larue M. Impact of systematic IVIG prophylaxis on the rate of severe infections in patients treated with anti-BCMA bispecific antibodies for relapsed\/refractory multiple myeloma. Poster presented at: Congr\u00e8s de la Soci\u00e9t\u00e9 Fran\u00e7aise d\u2019H\u00e9matologie (SFH). Paris, France; 2025. Poster C122 (P273)."},{"key":"ref68","unstructured":"elrexfio_decision_et_avisct_renouv_ap292.pdf. Available from: https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2024-03\/elrexfio_decision_et_avisct_renouv_ap292.pdf. Accessed June 10, 2025."},{"key":"ref69","unstructured":"put.pdf. Available from: https:\/\/www.ap-teclistamab.fr\/docs\/put.pdf. Accessed June 10, 2025."},{"key":"ref70","doi-asserted-by":"crossref","unstructured":"Smits F, Groen K, Korst C, et al. IVIG and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab [Oral presentation]. 22nd International Myeloma Society Annual Meeting (IMS 2025). Toronto, Canada; 2025.","DOI":"10.1016\/S2152-2650(25)03461-5"},{"key":"ref71","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1182\/blood-2024-200181","volume":"144","author":"D\u2019Souza","year":"2024","journal-title":"Blood"},{"key":"ref72","doi-asserted-by":"publisher","first-page":"NEJMoa2514663","DOI":"10.1056\/NEJMoa2514663","author":"Costa","year":"2025","journal-title":"N Engl J Med"},{"key":"ref73","doi-asserted-by":"publisher","first-page":"e039274c","DOI":"10.1097\/01.HS9.0000975284.03927.4c","volume":"7","author":"Grosicki","year":"2023","journal-title":"HemaSphere"},{"key":"ref74","doi-asserted-by":"publisher","first-page":"10148","DOI":"10.1182\/blood-2022-160173","volume":"140","author":"Krishnan","year":"2022","journal-title":"Blood"},{"key":"ref75","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41408-024-01081-z","volume":"14","author":"Rees","year":"2024","journal-title":"Blood Cancer J"},{"key":"ref76","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1182\/blood.2023022499","volume":"143","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"ref77","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1182\/blood.2023022823","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"key":"ref78","doi-asserted-by":"publisher","first-page":"e1257964","DOI":"10.1097\/01.HS9.0000967688.12579.64","volume":"7","author":"Offner","year":"2023","journal-title":"HemaSphere"},{"key":"ref79","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41408-025-01365-y","volume":"15","author":"Chalopin","year":"2025","journal-title":"Blood Cancer J"},{"key":"ref80","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1182\/bloodadvances.2021004418","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"key":"ref81","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1182\/blood-2024-211979","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"ref82","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s43018-020-0053-3","volume":"1","author":"Zavidij","year":"2020","journal-title":"Nat Cancer"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"6960","DOI":"10.1038\/s41467-021-26951-z","volume":"12","author":"Tirier","year":"2021","journal-title":"Nat Commun"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1182\/blood-2022-162709","volume":"140","author":"Cortes-Selva","year":"2022","journal-title":"Blood"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1016\/j.ccell.2018.02.007","volume":"33","author":"Nakamura","year":"2018","journal-title":"Cancer Cell"},{"key":"ref86","doi-asserted-by":"publisher","first-page":"8032","DOI":"10.1200\/JCO.2022.40.16_suppl.8032","volume":"40","author":"Rodr\u00edguez-Otero","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1158\/1078-0432.CCR-19-2299","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"e805462a","DOI":"10.1097\/01.HS9.0000970100.80546.2a","volume":"7","author":"Paiva","year":"2023","journal-title":"HemaSphere"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv"},{"key":"ref90","unstructured":"Perrot A, Touzeau C, Rodr\u00edguez-Otero P, et al. Talquetamab + cetrelimab in patients with relapsed\/refractory multiple myeloma: initial safety and efficacy results from the phase 1b TRIMM-3 study. Presented at: European Hematology Association 2025 Congress. Milan, Italy; 2025:AbstractS200."},{"key":"ref91","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41577-024-01003-x","volume":"24","author":"De Jong","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1038\/s41590-024-01808-x","volume":"25","author":"De Jong","year":"2024","journal-title":"Nat Immunol"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"7100","DOI":"10.1182\/blood-2024-198751","volume":"144","author":"Banerjee","year":"2024","journal-title":"Blood"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"TPS8067","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS8067","volume":"41","author":"Touzeau","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref95","doi-asserted-by":"crossref","unstructured":"Raab M. Phase 2 study of teclistamab-based induction regimens in patients with transplant-eligible (TE) newly diagnosed multiple myeloma (NDMM): results from the GMMG-HD10\/DSMM-XX (MajesTEC-5) trial. Oral Abstract #493. Presented at: 66th American Society of Hematology Annual Meeting and Exposition. San Diego, US; 2024.","DOI":"10.1182\/blood-2024-206003"},{"key":"ref96","unstructured":"Zamagni E, Silzle T, \u0160pi\u010dka I, et al. Phase 3 study of teclistamab with lenalidomide, teclistamab alone, and lenalidomide alone as maintenance therapy in newly diagnosed multiple myeloma post-autologous stem cell transplant: safety run-in results from the EMN30\/MajesTEC-4 trial. Oral Presentation presented at: The 66th American Society of Hematology (ASH) Annual Meeting. San Diego, CA; 2024."},{"key":"ref97","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood.2023023616","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1038\/s41408-025-01314-9","volume":"15","author":"Dima","year":"2025","journal-title":"Blood Cancer J"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1182\/blood.2022015526","volume":"141","author":"Cohen","year":"2023","journal-title":"Blood"},{"key":"ref100","doi-asserted-by":"publisher","first-page":"2766","DOI":"10.1200\/JCO-25-00760","volume":"43","author":"Jagannath","year":"2025","journal-title":"J Clin Oncol"},{"key":"ref101","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1182\/blood.2024026216","volume":"146","author":"Sidana","year":"2025","journal-title":"Blood"},{"key":"ref102","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/s41408-023-00886-8","volume":"13","author":"Ferreri","year":"2023","journal-title":"Blood Cancer J"}],"container-title":["Biologics: Targets and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/110944","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/110944","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T07:15:14Z","timestamp":1768288514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/teclistamab-for-relapsed-or-refractory-multiple-myeloma-a-review-of-ef-peer-reviewed-fulltext-article-BTT"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":102,"URL":"https:\/\/doi.org\/10.2147\/btt.s539066","relation":{},"ISSN":["1177-5491"],"issn-type":[{"value":"1177-5491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}